Ionis Pharmaceuticals

Aro Biotherapeutics is focused on the development of a new protein drug platform called Centyrins, designed to achieve better efficacy and safety profiles for patients with cancer and other serious diseases. Centyrins are small, non-antibody protein scaffolds that can be expressed as multi-specifics with novel therapeutic mechanisms of action. Centyrins are also ideal for the targeted delivery of complex drug payloads, including nucleic acids.

Akcea Therapeutics, Inc. is a biopharmaceutical company dedicated to developing and commercializing medicines for serious and rare diseases, particularly those related to cardiometabolic disorders caused by lipid abnormalities. The company's product portfolio includes TEGSEDI, an antisense medication aimed at reducing transthyretin protein production, and WAYLIVRA, which has completed Phase III clinical studies for familial chylomicronemia syndrome and is also being evaluated for familial partial lipodystrophy. Akcea is advancing several other drug candidates, including AKCEA-APO(a)-LRx and AKCEA-ANGPTL3-LRx, both of which have completed Phase IIb studies for various lipid disorders. Additionally, the company is developing AKCEA-APOCIII-LRx and AKCEA-TTR-LRx for cardiovascular disease and transthyretin amyloidosis, respectively. Akcea Therapeutics is a subsidiary of Ionis Pharmaceuticals and has strategic collaborations with Novartis Pharma AG and PTC Therapeutics International Limited. The company is headquartered in Boston, Massachusetts and was incorporated in 2014.

Empirico is a company focused on developing an insights platform that leverages biological insights derived from human genetics to create new medicines. Its platform utilizes biological datasets and programmable biology to facilitate target discovery and development. This enables scientists to systematically generate, examine, and prioritize high-confidence therapeutic hypotheses, ultimately advancing the field of drug development through innovative approaches grounded in human genetic research.

Atlantic Healthcare plc is an international specialty pharmaceutical company based in Saffron Walden, United Kingdom, founded in 2006. The company is dedicated to the development and commercialization of pharmaceutical products that address niche unmet needs in the hospital and specialist care sector, particularly for patients with gastrointestinal diseases. Its key product, the Alicaforsen Enema, is an anti-inflammatory intercellular adhesion molecule inhibitor designed to treat pouchitis and ulcerative colitis by targeting a critical protein involved in the inflammation process. Atlantic Healthcare aims to provide innovative solutions for healthcare providers managing patients with these conditions, contributing to the growing demand within the pharmaceutical industry.

iCo Therapeutics Inc. is a biotechnology company based in Vancouver, Canada, that specializes in the identification, development, and commercialization of drug candidates for ocular and infectious diseases. The company focuses on in-licensed products, including iCo-008, a human monoclonal antibody currently in Phase II clinical trials for ulcerative colitis and bullous pemphigoid, and the Oral AmpB Delivery System, an oral formulation of Amphotericin B undergoing Phase 1b clinical trials for systemic fungal and parasitic infections. iCo Therapeutics employs a business model that emphasizes the acquisition and reformulation of drug candidates, particularly those that are off-patent or nearing commercialization, to expand their therapeutic applications. The company operates primarily in Canada and Australia, concentrating on developing drug delivery technologies to enhance the efficacy and reach of its therapeutic offerings.